Boehringer Ingelheim acquires all ViraTherapeutics shares

Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies  Boehringer Ingelheim exercises its option to acquire all shares of oncolytic virus company ViraTherapeuticsViraTherapeutics will operate in Innsbruck, Austria as a distinct unit of Boehringer Ingelheim ’s Discovery Research organization, maintaining its innovative biotech heritage and close connections to the Medical University of Innsbruck and the regional scientific communityAcquisition strengthens Boehringer Ingelheim ’s commitment to research and development of viral-based immuno-oncology treatment options aimed at transforming the lives of patients 
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news